Recent Quotes (30 days)

You have no recent quotes
chg | %

Optos Plc  

(Public, LON:OPTS)   Watch this stock  
Find more results forOPTS
127.25
+5.00 (4.09%)
May 20 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 123.25 - 130.00
52 week 108.20 - 230.59
Open 123.25
Vol / Avg. 142,083.00/257.00
Mkt cap 91.39M*
P/E 7.99
Div/yield     -
EPS 0.16*
Shares 71.82M
Beta     -
Inst. own     -
*GBP
May 16, 2013
Interim 2013 Optos PLC Earnings Presentation (London)
Feb 21, 2013
OPTOS PLC Annual General Meeting
  

Key stats and ratios

Q3 (Sep '12) 2012
Net profit margin 13.18% 9.11%
Operating margin 16.36% 11.90%
EBITD margin - 24.43%
Return on average assets 13.58% 9.21%
Return on average equity 25.11% 16.07%
Employees 426 -
Carbon Disclosure Rating - -

Address

Queensferry House Enterprise Way, Carnegie Campus
DUNFERMLINE, SCO KY11 8GR
United Kingdom - Map
+44-1383-843300 (Phone)
+44-1383-843333 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance
Discussion Group - Google Finance

Description

Optos Plc is a retinal imaging company. The Company�s medical devices produce ultra-widefield, high resolution digital images of approximately 82% of the retina in a single capture. The images provide enhanced clinical information for ophthalmic professionals, facilitating the early detection, management and treatment of both eye and non-eye disorders and diseases that may exhibit in the retina. The Company�s widefield retinal imaging technology, combined with the specific data that can be derived from optical coherence tomography (OCT) images, has the potential to offer ophthalmologists and optometrists the tools for disease diagnosis and management. The optomap images provide enhanced clinical information, which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina, such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration.

Officers and directors

Roy G. Davis Chief Executive Officer, Executive Director
Louisa Burdett Chief Financial Officer, Executive Director
Michael E. Geraghty President - Global Sales
Age: 53
Tom Motta Chief Operating Officer
Dan Wood Senior Vice President - Global Customer Facing Operations
Alex Warnock Chief Technology Officer
Jim Milkay Chief Information Officer
Richard Coose Vice President - Global Human Resources
Anne Marie Cairns Vice President - Clinical
Robert Tweedlie Vice President - Global Quality Assurance & Regulatory Affairs